Suita, Japan

Wataru Hirose

This inventor holds 1 USPTO granted patent. Top assignee: Sumitomo Pharma Co., Ltd.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Wataru Hirose. Retrieved from https://idiyas.com/inventor/wataru-hirose-5g2c4umx

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

Average Co-Inventor Count = 1.0


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Wataru Hirose: Innovator in Anticancer Research

Introduction

Wataru Hirose is a notable inventor based in Suita, Japan. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds with potential therapeutic applications.

Latest Patents

Hirose holds a patent for an optically active bridged piperidine derivative. This invention relates to a compound that has shown an anticancer effect by inhibiting the binding between a MLL fusion protein and menin. The compound is characterized by a specific formula, where certain variables can represent hydrogen atoms or other groups, and it may also exist as a pharmaceutically acceptable salt.

Career Highlights

Wataru Hirose is associated with Sumitomo Pharma Co., Ltd., a company known for its commitment to advancing healthcare through innovative pharmaceutical solutions. His work focuses on developing new treatments that target specific cancer pathways, showcasing his dedication to improving patient outcomes.

Conclusion

Wataru Hirose's contributions to anticancer research through his patented inventions highlight the importance of innovation in the pharmaceutical industry. His work continues to pave the way for new therapeutic options in the fight against cancer.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…